Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUNAR: Rosuvastatin vs Atorvastatin in ACS
NCT00214630Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2003
- Primary completion
- Aug 2007
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of rosuvastatin in acute coronary syndrome (ACS) (3 arms), sponsored by AstraZeneca. Primary endpoint: Percentage change from baseline in LDL-C at 12 weeks. Started Dec 2003; status: completed.
02
Drugs
rosuvastatin
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT00214630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00214630.